Please login to the form below

Not currently logged in
Email:
Password:

Redx Pharma appoints new chief medical officer

Dr Andrew Saunders joins the UK biotech from Lytix Biopharma

Dr Andrew SaundersDrug discovery and development group Redx Pharma has appointed Dr Andrew Saunders as its chief medical officer (CMO), a role that will see him work with the R&D team fronting the clinical development of the company’s lead candidate.

Dr Saunders has worked in the oncology field for over 25 years and has experience in all aspects of the clinical development of oncology drugs.

He joins the UK biotech from Lytix Biopharma, a Norweigan immuno-oncology biotech, where he also served as CMO.

During his career, Dr Saunders has held several roles for both pharma and biotech companies, including Genzyme - now part of Sanofi, Roche, and Eli Lilly.

Ian Ross, chairman of Redx Pharma, said: “Dr Saunders brings a wealth of relevant experience and expertise in the clinical development of oncology drugs, which will be invaluable as the company transforms into a clinical stage company with the anticipated commencement of the first phase I study on lead compound RXC004.”

25th January 2018

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics